Cargando…

New advances in the treatment of generalized lipodystrophy: role of metreleptin

Recombinant methionyl human leptin or metreleptin is a synthetic leptin analog that has been trialed in patients with leptin-deficient conditions, such as leptin deficiency due to mutations in the leptin gene, hypothalamic amenorrhea, and lipodystrophy syndromes. These syndromes are characterized by...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rodriguez, Alexander J, Mastronardi, Claudio A, Paz-Filho, Gilberto J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4577254/ https://www.ncbi.nlm.nih.gov/pubmed/26396524 http://dx.doi.org/10.2147/TCRM.S66521

Ejemplares similares

Metreleptin Treatment in Three Patients with Generalized Lipodystrophy
por: Musso, Carla, et al.
Publicado: (2017)

Metreleptin therapy in LMNA-linked lipodystrophies
por: Vatier, Camille, et al.
Publicado: (2015)

Suggestive Evidence for an Antidepressant Effect of Metreleptin Treatment in Patients with Lipodystrophy
por: Vieira, Diana Branco, et al.
Publicado: (2022)

SAT089 Natural History Of Generalized Lipodystrophy Following Early Vs. Late Metreleptin Treatment
por: Brush, Maiah, et al.
Publicado: (2023)

Metreleptin treatment for congenital generalized lipodystrophy type 4 (CGL4): a case report
por: Takeyari, Shinji, et al.
Publicado: (2019)

Diagnosis of acquired generalized lipodystrophy in a single patient with T-cell lymphoma and no exposure to Metreleptin
por: Esfandiari, Nazanene H., et al.
Publicado: (2019)

Metreleptin and Metformin Use in an Infant With Congenital Generalized Lipodystrophy Secondary to AGPAT2 Mutation
por: Schweisberger, Cintya, et al.
Publicado: (2021)

Risk factors for diabetic foot ulcers in metreleptin naïve patients with lipodystrophy
por: Saydam, O, et al.
Publicado: (2021)

SUN-607 Iron Parameters in Patients with Partial Lipodystrophy and Impact of Metreleptin Therapy
por: Boutros, Sabine, et al.
Publicado: (2020)

FRI056 Effect Of 48 Hour Of Metreleptin In Humans With Lipodystrophy During Controlled Feeding
por: Bukhari, Khulood M, et al.
Publicado: (2023)

Metreleptin Robustly Increases Resting-state Brain Connectivity in Treatment-naïve Female Patients With Lipodystrophy
por: Schlögl, Haiko, et al.
Publicado: (2023)

SAT-081 Advanced Lipoprotein Analysis Demonstrates Atherogenic Lipid Profile in Patients with Lipodystrophy That Improves after Metreleptin Treatment
por: Kinzer, Alexandra, et al.
Publicado: (2019)

Efficacy and Safety of Metreleptin in Patients with Partial Lipodystrophy: Lessons from an Expanded Access Program
por: Ajluni, Nevin, et al.
Publicado: (2016)

OR17-02 Changes in Hepatokines and Apolipoproteins Are Associated with Metabolic Response to Metreleptin in Partial Lipodystrophy
por: Akinci, Baris, et al.
Publicado: (2020)

SAT676 Severe Recurrent Pancreatitis In A Familial Partial Lipodystrophy Patient On Metreleptin
por: Sargin, Pinar, et al.
Publicado: (2023)

The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotide
por: Akinci, Baris, et al.
Publicado: (2020)

Metreleptin Supplementation for Improving Lipid and Glycemic Profiles in Acquired Diabetes Lipodystrophy: A Case Report
por: Nagayama, Ayako, et al.
Publicado: (2019)

Case Report: Metreleptin and SGLT2 Inhibitor Combination Therapy Is Effective for Acquired Incomplete Lipodystrophy
por: Nagayama, Ayako, et al.
Publicado: (2021)

OR33-02 The Treatment of Partial Lipodystrophy in the Setting of Neutralizing Antibody Against Metreleptin with Leptin Receptor Agonist REGN4461
por: Akinci, Baris, et al.
Publicado: (2020)

Metreleptin for the treatment of progressive encephalopathy with/without lipodystrophy (PELD) in a child with progressive myoclonic epilepsy: a case report
por: Pedicelli, Stefania, et al.
Publicado: (2020)

Therapeutic indications and metabolic effects of metreleptin in patients with lipodystrophy syndromes: Real‐life experience from a national reference network
por: Mosbah, Héléna, et al.
Publicado: (2022)

Case Report: Metreleptin Treatment in a Patient With a Novel Mutation for Familial Partial Lipodystrophy Type 3, Presenting With Uncontrolled Diabetes and Insulin Resistance
por: Lambadiari, Vaia, et al.
Publicado: (2021)

Metreleptin Treatment in a Boy with Congenital Generalized Lipodystrophy due to Homozygous c.465_468delGACT (p.T156Rfs*8) Mutation in the BSCL2 Gene: Results From the First-year
por: Özalkak, Şervan, et al.
Publicado: (2023)

Leptin therapy, insulin sensitivity, and glucose homeostasis
por: Paz-Filho, Gilberto, et al.
Publicado: (2012)

Recent advances in understanding lipodystrophy: a focus on lipodystrophy-associated cardiovascular disease and potential effects of leptin therapy on cardiovascular function
por: Bruder-Nascimento, Thiago, et al.
Publicado: (2019)

Untangling the Heterogeneity of Acquired Generalized Lipodystrophy
por: Cavdar, Umit, et al.
Publicado: (2021)

Cardiac Manifestations of Congenital Generalized Lipodystrophy
por: Sanon, Vani P., et al.
Publicado: (2016)

Adherence with metreleptin therapy and health self-perception in patients with lipodystrophic syndromes
por: Vatier, Camille, et al.
Publicado: (2019)

The Metreleptin Effectiveness and Safety Registry (MEASuRE): concept, design and challenges
por: Haymond, Morey W, et al.
Publicado: (2023)

Role of the IL-1 Pathway in Dopaminergic Neurodegeneration and Decreased Voluntary Movement
por: Stojakovic, Andrea, et al.
Publicado: (2016)

Targeted massively parallel sequencing for congenital generalized lipodystrophy
por: Costa-Riquetto, Aline D., et al.
Publicado: (2020)

Acquired partial lipoatrophy as graft-versus-host disease and treatment with metreleptin: two case reports
por: Shibata, Yusuke, et al.
Publicado: (2018)

Bone Mineral Density in Congenital Generalized Lipodystrophy: The Role of Bone Marrow Tissue, Adipokines, and Insulin Resistance
por: Freire, Erika Bastos Lima, et al.
Publicado: (2021)

The use of dried blood spot sampling for the measurement of HbA1c: a cross-sectional study
por: Mastronardi, Claudio A., et al.
Publicado: (2015)

Type 2 Diabetes With Partial Lipodystrophy of the Limbs: A new lipodystrophy phenotype
por: Strickland, Leah R., et al.
Publicado: (2013)

First Account of Psychological Changes Perceived by a Female with Congenital Leptin Deficiency upon Treatment with Metreleptin
por: Hebebrand, Johannes, et al.
Publicado: (2022)

Pathogenesis and treatment of human immunodeficiency virus lipodystrophy
por: Jain, Suyog Subhash, et al.
Publicado: (2012)

Rare case of congenital generalized lipodystrophy type 1
por: Shyam Sundar, C.M., et al.
Publicado: (2020)

Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges
por: Chiquette, Elaine, et al.
Publicado: (2017)

Lipodystrophies—Disorders of the Fatty Tissue
por: Knebel, Birgit, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_26uhqsjatios9s9j32vejt1gl3